Safety and Efficacy of Oral DMSA Therapy for Children with Autism Spectrum Disorders

Safety and Efficacy of Oral DMSA Therapy for Children with Autism Spectrum Disorders: Part A – Medical Results
http://www.biomedcentral.com/1472-6904/9/16

BMC Clinical Pharmacology 2009, 9:16doi:10.1186/1472-6904-9-16

Published: 23 October 2009

Abstract (provisional)

Background
This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.

Methods
Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.

Results
DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.

Conclusions
Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.

-AND-

Safety and Efficacy of Oral DMSA Therapy for Children with Autism Spectrum Disorders: Part B – Behavioral Results
http://www.biomedcentral.com/1472-6904/9/17

BMC Clinical Pharmacology 2009, 9:17doi:10.1186/1472-6904-9-17

Published: 23 October 2009

Abstract (provisional)

Background
This study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.

Methods
Phase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.

Results
The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. The degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p<0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r=0.60-0.87) and even better at the end of the study (r=0.63-0.94).

Conclusions
Overall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.

Read more on the links above….

You can leave a response, or trackback from your own site.

One Response to “Safety and Efficacy of Oral DMSA Therapy for Children with Autism Spectrum Disorders”

  1. Mom says:

    This is exactly what Andy Cutler has said all along – especially the part of dmsa raising glutathione. We have seen amazing progress using his low and frequent dose protocol.

Leave a Reply

You must be logged in to post a comment.

Powered by WordPress | Designed by: Virtual Server Hosting | Compare CD Rates Online, Bob Seger Tour and Registry Booster 2011